10x Genomics reported revenues of $165 million, down 10.3% year on year. This print exceeded analysts’ expectations by 3.5%. Despite the top-line beat, it was still a slower quarter for the company ...

A study by scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) introduces a more cost-effective, scalable ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.